TuisI9DN • FRA
add
Arbutus Biopharma Corp
Vorige sluiting
€2,86
Dagwisseling
€2,92 - €2,92
Jaarwisseling
€2,45 - €4,22
Markkapitalisasie
679,75 m USD
Gemiddelde volume
259,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,57 m | -26,62% |
Bedryfskoste | 8,43 m | 65,30% |
Netto inkomste | -12,53 m | 35,11% |
Netto winsgrens | -796,19 | 11,57% |
Wins per aandeel | -0,10 | 38,71% |
EBITDA | -15,34 m | 23,94% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 122,62 m | -2,68% |
Totale bates | 131,71 m | -8,79% |
Totale aanspreeklikheid | 34,34 m | -10,53% |
Totale ekwiteit | 97,37 m | — |
Uitstaande aandele | 191,48 m | — |
Prys om te bespreek | 5,61 | — |
Opbrengs op bates | -28,79% | — |
Opbrengs op kapitaal | -36,08% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -12,53 m | 35,11% |
Kontant van bedrywe | -10,32 m | 40,35% |
Kontant van beleggings | 13,41 m | -39,66% |
Kontant van finansiering | 1,42 m | -62,67% |
Netto kontantverandering | 4,48 m | -48,78% |
Beskikbare kontantvloei | -10,96 m | -18,93% |
Meer oor
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Gestig
2007
Webwerf
Werknemers
44
